AXQ Capital LP Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AXQ Capital LP decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 69.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 382 shares of the biopharmaceutical company's stock after selling 873 shares during the period. AXQ Capital LP's holdings in Regeneron Pharmaceuticals were worth $272,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Amundi increased its stake in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after purchasing an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after buying an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $127,489,000. Thrivent Financial for Lutherans lifted its position in Regeneron Pharmaceuticals by 1,272.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock worth $89,179,000 after acquiring an additional 116,074 shares during the period. Finally, KBC Group NV grew its stake in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Finally, Citigroup cut their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN traded down $4.31 on Thursday, hitting $635.83. 811,470 shares of the company's stock were exchanged, compared to its average volume of 640,846. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20. The stock has a market cap of $69.51 billion, a price-to-earnings ratio of 16.61, a P/E/G ratio of 2.34 and a beta of 0.27. The firm has a 50-day moving average price of $685.91 and a 200-day moving average price of $805.04. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $11.86 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.